(McCabe Message Partners) The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study) is testing whether solanezumab, an investigational treatment, can prevent or slow the development of symptoms associated with AD. Based on external findings from trials at later stages of AD dementia and ongoing observational studies in clinically normal individuals, the leadership of the A4 Study has decided to increase the dose of solanezumab and to extend the length of the A4 Study.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2uhzeXp
No comments:
Post a Comment